- Mechanism
- Suppresses gonadotropin release via pituitary desensitization
- Typical research dose
- 3.75 mg to 22.5 mg depot injection
- Route
- intramuscular, subcutaneous
- Half-life
- ~2.8 hours (immediate), 1-6 months (depot)
- Legal status
- FDA Approved
Overview
Triptorelin is a synthetic decapeptide and potent gonadotropin-releasing hormone (GnRH) agonist designed to regulate systemic hormone production. By initially stimulating and subsequently downregulating the pituitary gland, this peptide effectively suppresses the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Clinically approved under brand names like Trelstar and Decapeptyl, Triptorelin is primarily utilized in the management of hormone-dependent conditions such as advanced prostate cancer, endometriosis, and central precocious puberty. Ongoing research continues to explore broader Triptorelin benefits in reproductive medicine and targeted endocrine therapies.
Potential Benefits
- Prostate Cancer Management: Triptorelin effectively lowers testosterone to castration levels, slowing the progression of advanced hormone-dependent prostate cancer Plosker & Brogden, 1994.
- Endometriosis Relief: By suppressing ovarian estrogen production, the Triptorelin peptide alleviates pelvic pain and significantly reduces the size of endometrial lesions.
- Central Precocious Puberty Treatment: It halts premature sexual development in children by normalizing gonadotropin and sex steroid levels to prepubertal states.
- Uterine Fibroid Reduction: Preoperative administration of Triptorelin shrinks fibroid volume, facilitating easier and safer surgical removal procedures.
- In Vitro Fertilization (IVF) Support: The peptide prevents premature ovulation during controlled ovarian stimulation protocols, improving outcomes in assisted reproductive technologies.
- Breast Cancer Adjuvant Therapy: In premenopausal women, it suppresses ovarian function to reduce recurrence risks in hormone-receptor-positive breast cancer.
Side Effects
Common side effects:
- Hot flashes and excessive sweating
- Decreased libido and erectile dysfunction
- Injection site reactions including pain and redness
- Fatigue and generalized weakness
- Mood swings or depressive symptoms
Rare or serious side effects:
- Decreased bone mineral density and osteoporosis risk
- Pituitary apoplexy in patients with pre-existing adenomas
- Severe allergic reactions or anaphylaxis
- Spinal cord compression during the initial testosterone flare
Triptorelin is FDA-approved but should only be used under medical supervision. Consult a qualified healthcare provider before use.
Mechanism of Action
Initial receptor activation occurs when the Triptorelin peptide binds to GnRH receptors in the anterior pituitary gland, causing a temporary surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This transient flare effect leads to a brief increase in gonadal steroid production, such as testosterone in males and estrogen in females.
Subsequent receptor downregulation follows continuous exposure to Triptorelin, desensitizing the pituitary gland within two to four weeks. This profound suppression halts gonadotropin release, effectively inducing a reversible state of medical castration or menopause that starves hormone-dependent tissues of their primary growth signals.
Origin & History
Synthetic development of Triptorelin began in the 1970s following the Nobel Prize-winning discovery of the natural GnRH structure by Andrew Schally and Roger Guillemin. Researchers modified the native decapeptide by substituting the sixth amino acid (glycine) with D-tryptophan, significantly enhancing its binding affinity and extending its half-life against enzymatic degradation.
Regulatory milestones were achieved when the FDA approved Triptorelin under the brand name Trelstar in 2000 for the palliative treatment of advanced prostate cancer. Since then, its clinical indications have expanded globally to include endometriosis, precocious puberty, and assisted reproduction, solidifying its status as a cornerstone in endocrine pharmacology.